Join
Live feed
·
PRReleasevia Quantisnow
MapLight Therapeutics Inc. logo

MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia

ByQuantisnow·Wall Street's wire, on your screen.
MPLT· MapLight Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MPLT (MapLight Therapeutics Inc.) and more on Quantisnow.